Literature DB >> 24732151

Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner.

Jean-Dominique Gallezot1, Ming-Qiang Zheng2, Keunpoong Lim2, Shu-fei Lin2, David Labaree2, David Matuskey3, Yiyun Huang2, Yu-Shin Ding4, Richard E Carson2, Robert T Malison5.   

Abstract

UNLABELLED: (11)C-(+)-4-propyl-9-hydroxynaphthoxazine ((11)C-(+)-PHNO) is an agonist radioligand for imaging dopamine D2 and D3 receptors in the human brain with PET. In this study we evaluated the reproducibility of (11)C-(+)-PHNO binding parameters using a within-day design and assessed parametric imaging methods.
METHODS: Repeated studies were performed in 8 subjects, with simultaneous measurement of the arterial input function and plasma free fraction. Two (11)C-(+)-PHNO scans for the same subject were separated by 5.4 ± 0.7 h. After compartment models were evaluated, (11)C-(+)-PHNO volumes of distribution (V(T)) and binding potentials relative to the concentration of tracer in plasma (BP(P)), nondisplaceable tracer in tissue (BP(ND)), and free tracer in tissue (BP(F)) were quantified using the multilinear analysis MA1 method, with the cerebellum as the reference region. Parametric images of BP(ND) were also computed using the simplified reference tissue model (SRTM) and SRTM2.
RESULTS: The test-retest variability of (11)C-(+)-PHNO BP(ND) was 9% in D2-rich regions (caudate and putamen). Among D3-rich regions, variability was low in the pallidum (6%) but higher in substantia nigra (19%), thalamus (14%), and hypothalamus (21%). No significant mass carry-over effect was observed in D3-rich regions, although a trend in BP(ND) was present in the substantia nigra (-14% ± 15%). Because of the relatively fast kinetics, low-noise BP(ND) parametric images were obtained with both SRTM and SRTM2 without spatial smoothing.
CONCLUSION: (11)C-(+)-PHNO can be used to compute low-noise parametric images in both D2- and D3-rich regions in humans.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  agonist; dopamine D2 receptor; dopamine D3 receptor; positron emission tomography; test–retest study

Mesh:

Substances:

Year:  2014        PMID: 24732151      PMCID: PMC4201637          DOI: 10.2967/jnumed.113.132928

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

Review 1.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

2.  Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET).

Authors:  Eugenii A Rabiner; Marc Laruelle
Journal:  Int J Neuropsychopharmacol       Date:  2010-02-11       Impact factor: 5.176

3.  Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography.

Authors:  Kati Alakurtti; Sargo Aalto; Jarkko J Johansson; Kjell Någren; Terhi Tuokkola; Vesa Oikonen; Matti Laine; Juha O Rinne
Journal:  J Cereb Blood Flow Metab       Date:  2010-05-05       Impact factor: 6.200

4.  Affinity and selectivity of [¹¹C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo.

Authors:  Jean-Dominique Gallezot; John D Beaver; Roger N Gunn; Nabeel Nabulsi; David Weinzimmer; Tarun Singhal; Mark Slifstein; Krista Fowles; Yu-Shin Ding; Yiyun Huang; Marc Laruelle; Richard E Carson; Eugenii A Rabiner
Journal:  Synapse       Date:  2012-02-24       Impact factor: 2.562

5.  Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride.

Authors:  Fumitoshi Kodaka; Hiroshi Ito; Yasuyuki Kimura; Saori Fujie; Harumasa Takano; Hironobu Fujiwara; Takeshi Sasaki; Kazuhiko Nakayama; Christer Halldin; Lars Farde; Tetsuya Suhara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-14       Impact factor: 9.236

6.  In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.

Authors:  Ragy R Girgis; Xiaoyan Xu; Nobumi Miyake; Balu Easwaramoorthy; Roger N Gunn; Eugenii A Rabiner; Anissa Abi-Dargham; Mark Slifstein
Journal:  Neuropsychopharmacology       Date:  2010-12-22       Impact factor: 7.853

7.  First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study.

Authors:  Matthäus Willeit; Nathalie Ginovart; Ariel Graff; Pablo Rusjan; Irina Vitcu; Sylvain Houle; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Neuropsychopharmacology       Date:  2007-04-04       Impact factor: 7.853

8.  Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy.

Authors:  Andri C Tziortzi; Graham E Searle; Sofia Tzimopoulou; Cristian Salinas; John D Beaver; Mark Jenkinson; Marc Laruelle; Eugenii A Rabiner; Roger N Gunn
Journal:  Neuroimage       Date:  2010-06-30       Impact factor: 6.556

9.  Mathematical modelling of [¹¹C]-(+)-PHNO human competition studies.

Authors:  Graham E Searle; John D Beaver; Andri Tziortzi; Robert A Comley; Massimo Bani; Giulia Ghibellini; Emilio Merlo-Pich; Eugenii A Rabiner; Marc Laruelle; Roger N Gunn
Journal:  Neuroimage       Date:  2012-11-30       Impact factor: 6.556

10.  Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.

Authors:  Rajesh Narendran; W Gordon Frankle; N Scott Mason; Charles M Laymon; Brian J Lopresti; Julie C Price; Steve Kendro; Shivangi Vora; Maralee Litschge; James M Mountz; Chester A Mathis
Journal:  Synapse       Date:  2009-07       Impact factor: 2.562

View more
  23 in total

1.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

2.  Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Jun Ku Chung; Philip Gerretsen; Gagan Fervaha; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Alan Wilson; Ariel Graff-Guerrero
Journal:  Soc Neurosci       Date:  2016-02-29       Impact factor: 2.083

3.  First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430.

Authors:  Mika Naganawa; Rikki N Waterhouse; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Sanela Tarabar; Nicholas DeMartinis; Adam Ogden; Anindita Banerjee; Yiyun Huang; Richard E Carson
Journal:  J Nucl Med       Date:  2016-04-21       Impact factor: 10.057

4.  Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO.

Authors:  Mark Slifstein; Anissa Abi-Dargham; Ragy R Girgis; Raymond F Suckow; Thomas B Cooper; Chaitanya R Divgi; Pierre Sokoloff; Ludovic Leriche; Patrick Carberry; Shunichi Oya; Simon K Joseph; Marlène Guiraud; Agnès Montagne; Valérie Brunner; Florence Gaudoux; Françoise Tonner
Journal:  Psychopharmacology (Berl)       Date:  2019-11-26       Impact factor: 4.530

5.  Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746.

Authors:  Jean-Dominique Gallezot; Beata Planeta; Nabeel Nabulsi; Donna Palumbo; Xiaoxi Li; Jing Liu; Carolyn Rowinski; Kristin Chidsey; David Labaree; Jim Ropchan; Shu-Fei Lin; Aarti Sawant-Basak; Timothy J McCarthy; Anne W Schmidt; Yiyun Huang; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

6.  A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.

Authors:  Ragy R Girgis; Andy Forbes; Anissa Abi-Dargham; Mark Slifstein
Journal:  Neuropsychopharmacology       Date:  2019-12-17       Impact factor: 7.853

7.  Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia.

Authors:  Huai-Hsuan Tseng; Jeremy J Watts; Michael Kiang; Ivonne Suridjan; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

8.  Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Authors:  Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero
Journal:  Synapse       Date:  2016-07-11       Impact factor: 2.562

9.  First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer.

Authors:  Mika Naganawa; Nabeel Nabulsi; Shannan Henry; David Matuskey; Shu-Fei Lin; Lawrence Slieker; Adam J Schwarz; Nancy Kant; Cynthia Jesudason; Kevin Ruley; Antonio Navarro; Hong Gao; Jim Ropchan; David Labaree; Richard E Carson; Yiyun Huang
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

10.  Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding.

Authors:  Kelly Smart; Jean-Dominique Gallezot; Nabeel Nabulsi; David Labaree; Ming-Qiang Zheng; Yiyun Huang; Richard E Carson; Ansel T Hillmer; Patrick D Worhunsky
Journal:  Neuroimage       Date:  2020-03-19       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.